Crohn’s Disease Treatment in Dallas, TX

What Is Crohn’s Disease?

Crohn’s disease is a chronic inflammatory bowel disease (IBD) that causes persistent inflammation of the gastrointestinal (GI) tract. Unlike ulcerative colitis, which is limited to the colon, Crohn’s disease can affect any part of the digestive system from the mouth to the anus, though it most commonly involves the terminal ileum (the last section of the small intestine) and the colon. The condition affects approximately 500,000 people in the United States and is one of the two major forms of IBD, alongside ulcerative colitis.

What distinguishes Crohn’s disease from other inflammatory conditions of the gut is the nature of its inflammation. Crohn’s causes transmural inflammation, meaning it extends through the entire thickness of the bowel wall — from the innermost mucosal lining through the muscle layers to the outer serosal surface. This deep, penetrating inflammation is what gives rise to many of the hallmark complications of Crohn’s disease, including strictures (narrowing of the intestine), fistulas (abnormal connections between the intestine and other structures), and abscesses (pockets of infection).

Crohn’s disease is a relapsing-remitting condition, meaning patients typically experience periods of active disease (flares) alternating with periods of remission when symptoms subside. The disease follows an unpredictable course, and without appropriate treatment, chronic inflammation can lead to progressive bowel damage over time. According to guidelines published by the American College of Gastroenterology (ACG) and the American Gastroenterological Association (AGA), early diagnosis and proactive treatment are essential to prevent irreversible complications and preserve bowel function.

At Texas Gut Health in Sachse, TX, Dr. Jaison John provides comprehensive Crohn’s disease care for patients throughout the Dallas-Fort Worth area. Dr. John completed his gastroenterology fellowship at UT Medical Branch, where he served as Chief Fellow, and his internal medicine residency at UT Austin Dell Medical School, where he served as Chief Resident. He holds dual board certifications from the American Board of Internal Medicine in both internal medicine and gastroenterology, bringing fellowship-level IBD expertise to every patient he treats.

Symptoms of Crohn’s Disease

The symptoms of Crohn’s disease vary depending on which part of the gastrointestinal tract is affected, the severity of inflammation, and whether complications such as strictures or fistulas are present. Symptoms can range from mild to debilitating and may develop gradually or appear suddenly. Common symptoms include:

• Abdominal pain and cramping — Persistent pain, often in the lower right abdomen, is one of the most common symptoms. Pain may worsen after eating and can range from a dull ache to severe cramping.
• Chronic diarrhea — Frequent, loose, or watery bowel movements are a hallmark of active Crohn’s disease. Some patients may have 10 or more bowel movements per day during a flare. Diarrhea may sometimes contain blood or mucus.
• Rectal bleeding — Blood in the stool or on toilet tissue can occur, particularly when the colon or rectum is involved. While not as universally present as in ulcerative colitis, bloody diarrhea is a significant symptom that warrants urgent evaluation.
• Fatigue — Persistent, overwhelming tiredness is reported by the majority of Crohn’s patients and can be caused by active inflammation, anemia, nutritional deficiencies, or the body’s ongoing immune response.
• Unintentional weight loss — Reduced appetite, malabsorption of nutrients, and the metabolic demands of chronic inflammation often lead to significant weight loss.
• Fever — Low-grade fevers are common during active disease. A high fever may indicate an abscess or other serious complication.
• Mouth sores (aphthous ulcers) — Painful sores on the inner lining of the mouth are common in Crohn’s patients and may precede or accompany intestinal flares.
• Perianal disease — Crohn’s disease frequently affects the area around the anus, causing pain, swelling, drainage, skin tags, fissures (tears), fistulas, or abscesses. Perianal involvement is reported in up to one-third of Crohn’s patients over their lifetime.
• Nausea and vomiting — These symptoms may occur when the disease causes narrowing (stricture) of the intestine, particularly in the small bowel, leading to partial or complete bowel obstruction.

Causes and Risk Factors

The exact cause of Crohn’s disease is not fully understood, but current research indicates that it results from a complex interaction between genetic susceptibility, immune system dysfunction, and environmental triggers. The disease is not caused by anything a patient did or ate, and it is not contagious.

Immune System Dysregulation

Crohn’s disease is fundamentally a disorder of the immune system. In healthy individuals, the immune system protects against harmful bacteria and pathogens in the gut while tolerating the trillions of beneficial microorganisms that make up the intestinal microbiome. In Crohn’s disease, the immune system loses this balance and mounts an abnormal, sustained inflammatory response against the intestinal tissue itself. This chronic, unchecked inflammation is what damages the bowel wall over time. Key immune pathways involved include tumor necrosis factor-alpha (TNF-alpha), interleukins (IL-12 and IL-23), and integrin-mediated immune cell trafficking — all of which are now targets for biologic therapies.

Genetics

Genetics play a significant role in Crohn’s disease susceptibility. Researchers have identified more than 200 genetic loci associated with IBD, with the NOD2/CARD15 gene being the most well-studied risk gene for Crohn’s disease. Variants in the NOD2 gene impair the body’s ability to recognize and respond to bacterial components in the gut, leading to an exaggerated inflammatory response. Having a first-degree relative (parent, sibling, or child) with Crohn’s disease increases your risk five- to eight-fold, and the disease is more common among people of Ashkenazi Jewish descent.

Environmental Triggers

Several environmental factors have been linked to the development or worsening of Crohn’s disease:

• Smoking — Cigarette smoking is the single most significant modifiable risk factor for Crohn’s disease. Smokers are approximately twice as likely to develop Crohn’s disease compared to non-smokers, and smoking worsens disease severity, increases the risk of flares and complications, and reduces response to treatment. Quitting smoking is one of the most impactful steps a Crohn’s patient can take to improve their disease course.
• Age of onset — Crohn’s disease can develop at any age, but it is most commonly diagnosed between the ages of 15 and 35. A second, smaller peak in diagnosis occurs between ages 50 and 70.
• Geographic and lifestyle factors — Crohn’s disease is more prevalent in industrialized nations and urban environments, suggesting that factors associated with a Western lifestyle — such as diet, hygiene, antibiotic use, and reduced exposure to diverse microorganisms — may contribute to disease development.
• Gut microbiome alterations — Patients with Crohn’s disease often have reduced diversity in their gut microbiome (dysbiosis) compared to healthy individuals. While it remains unclear whether dysbiosis is a cause or consequence of the disease, the gut microbiome is an active area of IBD research.
• Prior infections and antibiotics — Early-life antibiotic exposure and certain gastrointestinal infections have been associated with an increased risk of developing IBD in epidemiological studies.

How Crohn’s Disease Is Diagnosed

There is no single test that definitively diagnoses Crohn’s disease. Instead, diagnosis is based on a comprehensive evaluation that combines clinical history, physical examination, laboratory tests, endoscopic evaluation, imaging studies, and histopathology (tissue biopsy analysis). At Texas Gut Health, Dr. John uses a systematic, evidence-based approach aligned with ACG and AGA diagnostic guidelines to ensure an accurate diagnosis and thorough assessment of disease extent and severity.

Laboratory Tests

• Blood tests — Complete blood count (CBC) may reveal anemia or elevated white blood cell count. C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are inflammatory markers that are often elevated in active Crohn’s disease. A comprehensive metabolic panel can identify nutritional deficiencies, electrolyte imbalances, and liver or kidney involvement.
• Stool tests — Fecal calprotectin is a highly sensitive stool marker for intestinal inflammation and is widely used to distinguish IBD from non-inflammatory conditions such as irritable bowel syndrome (IBS). Stool cultures and Clostridioides difficile testing help rule out infectious causes of diarrhea.
• Serologic markers — Anti-Saccharomyces cerevisiae antibodies (ASCA) and perinuclear anti-neutrophil cytoplasmic antibodies (pANCA) can sometimes help differentiate Crohn’s disease from ulcerative colitis, though they are not definitive on their own.

Endoscopy

• Colonoscopy with biopsy — Colonoscopy is the primary diagnostic procedure for Crohn’s disease. It allows the gastroenterologist to directly visualize the colon and terminal ileum, identify characteristic findings such as aphthous ulcers, cobblestoning, skip lesions, and deep linear or serpiginous ulcers, and obtain tissue biopsies for histologic examination. Biopsy findings of non-caseating granulomas, while not always present, are highly suggestive of Crohn’s disease.
• Upper endoscopy (EGD) — In patients with upper GI symptoms or when upper tract involvement is suspected, an esophagogastroduodenoscopy may be performed to evaluate the esophagus, stomach, and duodenum.
• Capsule endoscopy — A wireless capsule camera can visualize the small bowel, which is not accessible by standard colonoscopy. Capsule endoscopy is particularly useful for evaluating suspected small bowel Crohn’s disease when other tests are inconclusive, though it must be used cautiously in patients with known strictures due to the risk of capsule retention.

Imaging Studies

• CT enterography (CTE) — This specialized CT scan uses oral contrast to distend the small bowel and provide detailed cross-sectional images. It can identify bowel wall thickening, strictures, fistulas, abscesses, and mesenteric inflammation with high sensitivity and is often the first-line imaging study for evaluating small bowel Crohn’s disease.
• MR enterography (MRE) — MRI-based imaging of the small bowel provides similar diagnostic information to CTE without ionizing radiation, making it preferred for younger patients and those requiring repeated imaging over time. MRI is also the gold standard for evaluating perianal Crohn’s disease, including fistulas and abscesses.
• Intestinal ultrasound — Increasingly used as a non-invasive, point-of-care tool to assess bowel wall thickness and detect complications. Intestinal ultrasound is gaining recognition in ACG guidelines as a valuable monitoring tool for IBD patients.

Treatment Options for Crohn’s Disease

The goals of Crohn’s disease treatment have evolved significantly over the past two decades. Current ACG and AGA guidelines emphasize a treat-to-target approach that aims not only to relieve symptoms but to achieve objective measures of disease control, including mucosal healing (healing of the intestinal lining as confirmed by endoscopy), normalization of inflammatory biomarkers, and prevention of disease progression and complications. Treatment is tailored to each patient based on disease severity, location, behavior (inflammatory, stricturing, or penetrating), and individual risk factors.

Aminosalicylates (5-ASAs)

Aminosalicylate medications such as mesalamine and sulfasalazine have a limited role in Crohn’s disease compared to ulcerative colitis. They may be considered for mild Crohn’s colitis (Crohn’s disease limited to the colon), but current guidelines generally do not recommend them as a primary treatment for most Crohn’s disease patients due to limited efficacy, particularly for small bowel disease.

Corticosteroids

Corticosteroids such as prednisone, methylprednisolone, and budesonide are effective at rapidly reducing inflammation and controlling symptoms during acute flares. Budesonide is a locally acting steroid with fewer systemic side effects and is often preferred for mild-to-moderate ileal or right-sided colonic Crohn’s disease. However, corticosteroids are not appropriate for long-term maintenance therapy due to significant side effects including bone loss, weight gain, diabetes, infections, and adrenal suppression. They do not promote mucosal healing and should be used as a bridge while steroid-sparing therapies take effect.

Immunomodulators

Immunomodulator medications suppress the overactive immune response that drives Crohn’s disease. Commonly used immunomodulators include:

• Azathioprine and 6-mercaptopurine (6-MP) — Thiopurine medications that are used for maintenance of remission and as combination therapy with biologic agents. They take 8 to 12 weeks to reach full effect and require regular blood monitoring for bone marrow suppression and liver toxicity.
• Methotrexate — An alternative immunomodulator that can induce and maintain remission in Crohn’s disease, administered by weekly injection. It is contraindicated in pregnancy and requires folic acid supplementation.

Biologic Therapies

Biologic therapies represent a major advancement in Crohn’s disease treatment. These are targeted medications derived from living cells that block specific molecules in the inflammatory cascade. Biologics are recommended for moderate-to-severe Crohn’s disease and are increasingly used earlier in the disease course (top-down therapy) to prevent bowel damage before it occurs. At Texas Gut Health, Dr. John offers comprehensive biologic management, including in-office infusion therapy for intravenous biologics.

• Anti-TNF agents (infliximab, adalimumab, certolizumab pegol) — These medications block tumor necrosis factor-alpha, a key inflammatory protein. Infliximab is administered by intravenous infusion, while adalimumab and certolizumab pegol are given by subcutaneous injection. Anti-TNF agents have the longest track record in Crohn’s disease and can induce remission, maintain remission, promote mucosal healing, and reduce the need for surgery.
• Anti-integrin therapy (vedolizumab) — Vedolizumab selectively blocks the migration of immune cells into the gut by targeting the alpha-4-beta-7 integrin. It is gut-selective, meaning it has fewer systemic immunosuppressive effects compared to anti-TNF agents. It is administered by intravenous infusion.
• Anti-IL-12/23 therapy (ustekinumab) — Ustekinumab blocks interleukin-12 and interleukin-23, two cytokines involved in the inflammatory pathway. It is given as an initial intravenous loading dose followed by subcutaneous maintenance injections and has demonstrated efficacy in patients who have failed anti-TNF therapy.
• Anti-IL-23 therapy (risankizumab) — Risankizumab selectively targets the p19 subunit of interleukin-23 and is approved for moderate-to-severe Crohn’s disease. It has shown strong efficacy for both induction and maintenance of remission.

Small Molecule Therapies

Small molecule therapies are oral medications that target specific intracellular signaling pathways involved in inflammation. Unlike biologics, they are taken as pills, which many patients find more convenient.

• Upadacitinib — A Janus kinase (JAK) inhibitor approved for moderate-to-severe Crohn’s disease. Upadacitinib works by blocking JAK enzymes involved in the signaling of multiple inflammatory cytokines. It is taken orally once daily and has shown significant efficacy in clinical trials for both induction and maintenance of remission, including in patients who have failed biologic therapies.

Combination Therapy

For patients with moderate-to-severe Crohn’s disease, combination therapy — using a biologic agent together with an immunomodulator (such as infliximab plus azathioprine) — has been shown in landmark clinical trials (the SONIC trial) to be more effective than either medication alone at achieving steroid-free remission and mucosal healing. Dr. John discusses the benefits and risks of combination therapy with each patient to determine the optimal treatment strategy.

Living with Crohn’s Disease

Crohn’s disease is a lifelong condition that requires ongoing medical management and self-care. With the right treatment plan and support, many patients with Crohn’s disease lead full, active lives. Here are key aspects of living with the disease that Dr. John discusses with his patients at Texas Gut Health.

Managing Flares

Flares — periods when disease activity increases and symptoms worsen — are an expected part of living with Crohn’s disease. Recognizing early signs of a flare (increasing diarrhea, abdominal pain, fatigue, or blood in the stool) and contacting your gastroenterologist promptly is critical. Do not adjust or stop your medications without guidance from your physician. Your care team may use laboratory markers (CRP, fecal calprotectin) and imaging to assess flare severity and guide treatment adjustments. Stress management, adequate sleep, and avoiding known triggers (such as NSAIDs and smoking) can also help reduce the frequency and severity of flares.

Diet and Nutrition

There is no single “Crohn’s diet” that works for everyone, but nutrition plays an important role in managing the disease. During active flares, a low-residue or low-fiber diet may help reduce symptoms by minimizing mechanical irritation of inflamed bowel. Between flares, most patients can follow a well-balanced diet. Common dietary strategies include eating smaller, more frequent meals; staying well hydrated; limiting dairy if lactose intolerant; avoiding heavily processed and fried foods; and identifying personal trigger foods through a food diary. Nutritional deficiencies — particularly iron, vitamin B12, vitamin D, folate, and zinc — are common in Crohn’s patients due to malabsorption and should be monitored and supplemented as needed.

Mental Health

Living with a chronic illness like Crohn’s disease can take a significant toll on mental health. Rates of anxiety and depression are substantially higher in IBD patients compared to the general population, and psychological distress can, in turn, worsen disease activity. Dr. John encourages patients to discuss mental health openly and may recommend referral to a psychologist or psychiatrist with experience in chronic illness management. Cognitive behavioral therapy, mindfulness-based stress reduction, and peer support groups (such as those offered by the Crohn’s & Colitis Foundation) have all been shown to benefit IBD patients.

Pregnancy Planning

Women with Crohn’s disease can have healthy pregnancies, but planning is essential. The most important step is achieving stable disease remission before conception, as active Crohn’s disease during pregnancy increases the risk of preterm birth, low birth weight, and other complications. Most IBD medications, including many biologics (infliximab, adalimumab, vedolizumab, ustekinumab), are considered low-risk during pregnancy based on current AGA guidelines. However, methotrexate is strictly contraindicated and must be discontinued at least 3 to 6 months before attempting pregnancy. Dr. John works closely with patients and their obstetric providers to create individualized pre-conception and pregnancy management plans.

Monitoring for Complications

Ongoing monitoring is a critical component of Crohn’s disease management. Regular follow-up appointments, laboratory testing (inflammatory markers, drug levels, nutritional labs), and periodic endoscopic or imaging assessments help ensure that treatment is effective and allow early detection of complications. Patients with long-standing Crohn’s colitis should undergo surveillance colonoscopies for colorectal cancer screening beginning 8 years after diagnosis, as recommended by AGA guidelines.

Complications of Crohn’s Disease

Without adequate treatment, Crohn’s disease can lead to serious complications that significantly impact quality of life and may require hospitalization or surgery. Understanding these potential complications underscores the importance of proactive, ongoing disease management.

• Intestinal strictures — Chronic inflammation can cause scarring and fibrosis that narrows the intestinal lumen, leading to partial or complete bowel obstruction. Symptoms include crampy abdominal pain, bloating, nausea, and vomiting after eating. Strictures may be managed with endoscopic balloon dilation or may require surgical resection.
• Fistulas — Transmural inflammation can create abnormal tunnels (fistulas) between the intestine and other structures, including other loops of bowel (enteroenteric), the bladder (enterovesical), the vagina (enterovaginal), or the skin surface (enterocutaneous). Perianal fistulas are especially common and can cause persistent drainage, pain, and recurrent infections. Treatment often requires a combination of medical therapy (biologics) and surgical intervention.
• Abscesses — Collections of pus can form within the abdominal cavity or in the perianal region as a result of deep tissue inflammation or fistula formation. Abscesses typically require drainage (percutaneous or surgical) along with antibiotic therapy.
• Colorectal cancer — Patients with long-standing Crohn’s disease involving the colon have an increased risk of developing colorectal cancer compared to the general population. This risk increases with longer disease duration and greater extent of colonic involvement. Regular surveillance colonoscopies with chromoendoscopy or high-definition white-light endoscopy are essential for early detection of dysplasia.
• Malnutrition and osteoporosis — Chronic inflammation, malabsorption (particularly in small bowel disease), and corticosteroid use can lead to deficiencies in essential nutrients and contribute to bone loss. DEXA scans and nutritional labs should be part of routine Crohn’s disease monitoring.
• Extraintestinal manifestations — Crohn’s disease can affect organ systems beyond the GI tract. Common extraintestinal manifestations include joint pain and arthritis (peripheral or axial), skin conditions (erythema nodosum, pyoderma gangrenosum), eye inflammation (uveitis, episcleritis), liver disease (primary sclerosing cholangitis), and kidney stones. These manifestations may or may not track with intestinal disease activity.
• Venous thromboembolism — IBD patients, particularly during active disease or hospitalization, have an increased risk of blood clots, including deep vein thrombosis (DVT) and pulmonary embolism (PE). Awareness and preventive measures are important components of comprehensive IBD care.

Frequently Asked Questions